Small molecule · Agonist of alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (CHRNA4) · developed by Pf Prism Cv
Varenicline is a small-molecule partial agonist that binds with high selectivity to alpha-4 beta-2 neuronal nicotinic acetylcholine receptors, producing weaker receptor activity than nicotine while blocking nicotine from activating them. It also binds with moderate affinity to the 5-HT3 receptor. Varenicline is studied in dry eye disease as a nasal spray formulation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 1, 2020). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07705893 | N/A | Dry Eye | Recruiting | OCUL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dry Eye
Updated Oct 25, 2026.